ArticleMolecular and clinical oncology2026
Pan-cancer analysis and experimental validation reveal UTP4 as a novel biomarker for gastric cancer.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
UTP4 is a critical component of ribosome biogenesis, and its dysregulation may contribute to cancer development. However, the role of UTP4 in cancer remains unclear. The present study comprehensively investigated the expression and prognostic significance of UTP4 across multiple cancers, with a particular focus on gastric cancer (GC). Integrated bioinformatics analysis of public datasets, including The Cancer Genome Atlas, revealed that UTP4 is frequently overexpressed in various tumors and associated with poor prognosis. Further analysis uncovered its correlations with genetic mutations, immune infiltration and immune checkpoint expression. Based on these findings and CRISPR-Cas9 screening predictions, the functional role of UTP4 in GC cells was experimentally validated. The results demonstrated that UTP4 knockdown significantly inhibited cell proliferation, migration and invasion. These findings highlight UTP4 as a novel pan-cancer biomarker and potential therapeutic target, providing a foundation for further clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.